Rhapsido
remibrutinib · Novartis Europharm Limited
AUTHORISED IN THE EUWhat Rhapsido is used for
Rhapsido is indicated for the treatment of chronic spontaneous urticaria (CSU) in adult patients with inadequate response to H1 antihistamine treatment.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Rhapsido
- Active substance
- remibrutinib
- Disease area
- Urticaria
- Medicine group
- Immunosuppressants
- ATC code
- L04AA60
- Marketing authorisation holder
- Novartis Europharm Limited
- Authorised in the EU since
- 2026
Official information
In the USA
Same active substance: Rhapsido
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Rhapsido used for?
Rhapsido is indicated for the treatment of chronic spontaneous urticaria (CSU) in adult patients with inadequate response to H1 antihistamine treatment.
What is the active substance in Rhapsido?
Rhapsido contains remibrutinib.
Who makes Rhapsido?
The EU marketing authorisation holder is Novartis Europharm Limited.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU